Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
By Colin Kellaher
Regeneron Pharmaceuticals has inked a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.
Regeneron on Thursday said it will make a $100 million up-front payment to Mammoth, including a $95 million equity investment in the biotechnology company.
Tarrytown, N.Y., biotechnology company Regeneron said it will pair its delivery technologies with Mammoth's proprietary Crispr-based gene-editing platform to advance in-vivo programs in multiple tissue and cell types.
Regeneron said Mammoth will be eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, along with royalties on sales of all collaboration products.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 25, 2024 08:04 ET (12:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?